Search
Search results
3 results found
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.
Rauh, Ulrike, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, et al. 2024. “BRD-810 Is a Highly Selective MCL1 Inhibitor With Optimized in Vivo Clearance and Robust Efficacy in Solid and Hematological Tumor Models.”. Nat Cancer.